Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9272253 | 0.79 | AKR1B1 (0.61) | PKMAKR1B1KMT2ALMNAADRA2A | |
| SCHEMBL3395963 | 0.78 | PKM (0.74) | PKMLMNATAAR1SMN1; SMN2HTT | |
| SCHEMBL1021475 | 0.77 | AKR1B1 (0.54) | PKMAKR1B1KMT2ALMNAADRA2A | |
| SCHEMBL1395814 | 0.77 | AKR1B1 (0.65) | PKMAKR1B1KMT2ALMNAADRA2A | |
| Hydrochloric Acid SCHEMBL1182809 | 0.76 | ADRA2A (0.55) | PKMAKR1B1KMT2ALMNAADRA2A | |
| SCHEMBL3714040 | 0.76 | PKM (1.00) | PKMKMT2ALMNAMEN1TAAR1 | |
| Hydrochloric Acid SCHEMBL5297667 | 0.76 | ADRA2A (0.65) | AKR1B1KMT2ALMNAADRA2ACYP3A4 | |
| SCHEMBL837828 | 0.74 | ADRA2A (0.55) | PKMAKR1B1KMT2ALMNAADRA2A | |
| SCHEMBL11822889 | 0.74 | KMT2A (0.53) | AKR1B1KMT2ALMNAADRA2ACYP3A4 | |
| SCHEMBL20541209 | 0.73 | BACE1 (0.44) | PKMKMT2AMAPTTAAR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160285-B | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-11-29 | — | — | CN | claimed |
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | claimed |
| CN-115160285-B | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | disclosed |
| US-20090326021-A1 | THIAZOLO NAPHTHYL ACIDS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-7605172-B2 | Thiazolo-naphthyl acids | WYETH (US) | 2009-10-20 | — | — | US | disclosed |
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1794138-A2 | THIAZOLO-NAPHTHYL ACIDS AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Wyeth (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060052420-A1 | Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023866-A2 | THIAZOLO-NAPHTHYL ACIDS AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1603905-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004072068-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326021-A1 | THIAZOLO NAPHTHYL ACIDS | SERPINE1, SERPINC1, SERPINB1 | PKM 3107/4885AKR1B1 219/4885KMT2A 4373/4885 |
| US-20060052420-A1 | Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease | SERPINE1, PLAT, SERPINC1 | PKM 1467/4885AKR1B1 588/4885KMT2A 4679/4885 |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PKM 3270/4885AKR1B1 1864/4885KMT2A 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.